Suppliers / Novo Nordisk Production Sas

Novo Nordisk Production Sas

France 2 duplicate records merged Updated 9 July 2026

Novo Nordisk Production Sas is a finished-dose manufacturer based in France. It appears in 19 regulatory filings across 6 regulators, without an active US DMF or CEP on file. Its filings concentrate with ARCSA (EC), UZPHARM (UZ) and NCELS (KZ). Its GMP standing is certified by ANSM (FR), EMA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 5 April 2023 as NAI.

0
active US DMFs
0
valid CEPs
4
registered plants 1 with an FDA FEI number
19
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 5 April 2023 NAI US FDA
  • 28 October 2022 VAI US FDA
  • 25 January 2018 NAI US FDA
  • 18 November 2016 NAI US FDA
  • 7 November 2014 NAI US FDA
  • 7 September 2012 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Chartres, United Arab Emirates Not on file
CHARTRES, France Not on file
Chartres, France Not on file
Ireland, Ireland 3002806873

Filings and GMP by regulator

Regulator Filings GMP certificates
ARCSA (EC) 7 None
UZPHARM (UZ) 4 None
NCELS (KZ) 3 1
INVIMA (CO) 2 None
DIGEMAPS (DO) 2 None
BOMRA (BW) 1 None
ANSM (FR) None 5
EMA None 3
ANVISA (Brazil) None 2

Scale

Year Revenue Exports Destinations
2024 $256.2M Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Novo Nordisk Production Sas comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 5 April 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported